- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
- Amarin Announces Results of Annual General Meeting of Shareholders
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
- Amarin Chairman & CEO Issue Letter to Shareholders
More ▼
Key statistics
As of last trade, Amarin Corporation PLC (EH3A:FRA) traded at 0.75, 32.74% above the 52 week low of 0.565 set on Nov 03, 2023.
52-week range
Open | 0.75 |
---|---|
High | 0.75 |
Low | 0.75 |
Bid | 0.76 |
Offer | 0.875 |
Previous close | 0.775 |
Average volume | 3.03k |
---|---|
Shares outstanding | 410.67m |
Free float | 390.11m |
P/E (TTM) | -- |
Market cap | 360.82m USD |
EPS (TTM) | -0.145 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 08:27 BST.
More ▼